Halyard Health, Inc. (HYH) Scheduled to Post Earnings on Tuesday
Halyard Health, Inc. (NYSE:HYH) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, October 31st. Analysts expect Halyard Health to post earnings of $0.47 per share for the quarter. Halyard Health has set its FY18 guidance at $1.85-2.05 EPS.
Halyard Health (NYSE:HYH) last released its earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.51 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.14. The firm had revenue of $399.20 million for the quarter, compared to analysts’ expectations of $399.16 million. Halyard Health had a net margin of 3.06% and a return on equity of 8.29%. Halyard Health’s quarterly revenue was down .2% on a year-over-year basis. During the same quarter last year, the company earned $0.45 EPS. On average, analysts expect Halyard Health to post $1.94 EPS for the current fiscal year and $2.09 EPS for the next fiscal year.
Halyard Health, Inc. (NYSE HYH) opened at 44.51 on Tuesday. The firm’s 50-day moving average is $45.21 and its 200 day moving average is $40.79. Halyard Health, Inc. has a 1-year low of $31.59 and a 1-year high of $46.63. The firm has a market cap of $2.08 billion, a PE ratio of 42.80 and a beta of 1.75.
COPYRIGHT VIOLATION NOTICE: This report was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/10/24/halyard-health-inc-hyh-scheduled-to-post-earnings-on-tuesday.html.
HYH has been the topic of several research reports. Zacks Investment Research downgraded shares of Halyard Health from a “buy” rating to a “sell” rating in a research report on Wednesday, October 4th. BidaskClub upgraded shares of Halyard Health from a “hold” rating to a “buy” rating in a research report on Saturday, August 19th. KeyCorp reiterated a “hold” rating on shares of Halyard Health in a research report on Tuesday, October 17th. Deutsche Bank AG upped their price target on shares of Halyard Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Finally, Stephens upgraded shares of Halyard Health from an “equal weight” rating to an “overweight” rating in a research report on Thursday, August 3rd. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Halyard Health currently has a consensus rating of “Buy” and a consensus price target of $42.25.
Halyard Health Company Profile
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.